phase 1
ii 1
randomized 1
trial 2
comparing 1
standard 1
low 1
dose 1
rituximab 1
combined 1
alemtuzumab 1
initial 1
treatment 1
progressive 1
chronic 2
lymphocytic 2
leukemia 2
older 1
patients 2
ecogacrin 1
cancer 1
research 1
group 1
e 1
targeting 1
b 2
cell 2
receptor 1
signaling 1
ibrutinib 2
diffuse 1
large 1
lymphoma 1
bruton 1
tyrosine 1
kinase 1
inhibitor 1
chemoimmunotherapy 1
